Examination of the follicular lymphoma international prognostic index (FLIPI) in the national lymphocare study (NLCS): A prospective US patient cohort treated predominantly in community practices

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 441-448

  Nooka, A K ^a   Nabhan, C ^b   Zhou, X ^c   Taylor, M D ^d   Byrtek, M ^d   Miller, T P ^e   Friedberg, J W ^f   Zelenetz, A D ^g   Link, B K ^h   Cerhan, J R ⁱ   Dillon, H ^j   Sinha, R ^a   Shenoy, P J ^a   Levy, D ^d   Dawson, K ^d   Hirata, J H ^d   Flowers, C R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

^d GENENTECH INC   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ Mayo Clinic   (United States)

^j The Leukemia & Lymphoma Society   (United States)

more..

Author keywords

Community practice; FLIPI; Follicular lymphoma; NLCS

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COHORT ANALYSIS; COMMUNITY CARE; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TIME TO TREATMENT; UNITED STATES;

EID: 84873831757     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds429     Document Type: Article

References (17)

1. Ganti A, Bociek R, Bierman P et al. Follicular lymphoma: expanding therapeutic options. Oncology (Huntingt) 2005; 19: 213-228.
2. Fisher RI, Kaminski MS, Wahl RL et al. Tositumomab and Iodine-131 Tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565-7573.
3. Swenson WT, Wooldridge JE, Lynch CF et al. Improved Survival of Follicular Lymphoma Patients in the United States. J Clin Oncol 2005; 23: 5019-5026.
4. Liu Q, Fayad L, Cabanillas F et al. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582-1589.
5. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
6. Friedberg JW, Taylor MD, Cerhan JR et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27: 1202-1208.
7. Eden J, Institute of Medicine (US). Committee on reviewing evidence to identify highly effective clinical services. Knowing what works in health care: a roadmap for the nation. Washington, DC: National Academies Press 2008.
8. Simera I, Altman DG, Moher D et al. Guidelines for reporting health research: the EQUATOR network's survey of guideline authors. PLoS Med 2008; 5: e139.
9. Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am 2008; 46: 175-198.
10. Nabhan C, Taylor M, Hirata J et al. Racial disparities in disease presentation, treatment, and response rates of follicular lymphoma (FL) in the United States (US): report from the National LymphoCare study (NLCS). ASH Annu Meeting Abstr 2009; 114: 1381.
11. Federico M, Vitolo U, Zinzani PL et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783-789.
12. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329: 987-994.
13. Perea G, Altes A, Montoto S et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005; 16: 1508-1513.
14. van de Schans SAM, Steyerberg EW, Nijziel MR et al. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 2009; 20: 1697-1702.
15. Buske C, Hoster E, Dreyling M et al. The follicular lymphoma international prognostic index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508.
16. Federico M, Bellei M, Marcheselli L et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27: 4555-4562.
17. Overman MJ, Feng L, Pro B et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 2008; 19: 553-559.